MYCO:CC News and Press, MYDECINE INNOVATIONS GROUP INC. From 02/23/22

Studies suggest that psychedelics such as psilocybin and MDMA offer health benefits when used to treat patients with depression and PTSD These results have encouraged scientists, psychotherapists, and entrepreneurs, who say that FDA approvals may be on the horizon Mydecine is playing ...

Recent studies have found that first responders and healthcare workers are displaying symptoms of PTSD that are similar to veterans who have served in combat. Researchers and healthcare providers believe that if administrators fail to find ways to offer relief to medical staff and hospit...

A new study has found that psychedelic substances can alter an individual’s core beliefs about the nature of free will, consciousness and reality. The study’s findings were reported in the “Scientific Reports” journal. The researchers’ objective was to ...

A recently published study has found that women may find it harder to stop smoking in comparison to men, especially on the first day after quitting. The study was conducted by researchers at the Mailman School of Public Health, Columbia University, and its findings were published in the &#...

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) , a biotechnology company aiming to transform the treatment of mental health and addiction disorders, has included a novel molecule — MYCO-005 — which has potential for heart-safe microdose enabling properties...

DENVER, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today announced the i...

Mydecine (NEO: MYCO) (OTC: MYCOF) , a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, was featured in a recent Bell2Bell Podcast episode in which its co-founder, chairman and CEO Josh Bartch shared the company’...

Last week, a House committee in the state of Utah passed a measure that would establish a task force to conduct research on and give recommendations for the therapeutic potential of psychedelic substances and regulations governing their legal use. The bill, which was sponsored by Rep. Brad...

Biotechnology company Mydecine Innovations Group is devoted to advancing the use of psychedelics for the treatment of mental illnesses and addiction Mydecine has necessary license to provide psilocybin and MDMA under Canada’s SAP program, which allows medical providers to request...